Documents

P2584

Sigma-Aldrich

Monoclonal Anti-Protein Kinase Cβ2 antibody produced in mouse

clone PK-B26, ascites fluid

Synonym(s):
Anti-PKC β2
MDL number:
NACRES:
NA.44

Quality Level

biological source

mouse

antibody form

ascites fluid

antibody product type

primary antibodies

clone

PK-B26, monoclonal

mol wt

antigen 80 kDa

contains

15 mM sodium azide

species reactivity

rat

application(s)

microarray: suitable
western blot: 1:8,000 using rat brain cytosol preparation

isotype

IgG1

conjugate

unconjugated

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

Gene Information

General description

Protein Kinase C (PKC, 76-93 kD) is a family of Ser/Thr specific protein kinases that perform key functions in numerous signalling pathways, in biological systems, through their various isoforms. The conventional PKC isoforms (cPKC) are PKC-α, β1, β2 and γ; activated by phosphatidylserine, calcium or phorbol esters. Proteolysis of PKC in vivo is thought to be mediated by calpains I and II. Calpains cleave PKC in the V3 hinge region to produce two distinct fragments, one comprising the N-terminal regulatory domain (30 kD) and the other fragment containing the C-terminal kinase domain (50 kD) that is catalytically active. Multiple functions such as, cellular and vascular regulations, angiogenesis, cell growth, apoptosis, changes in basement membrane thickness, extracellular matrix organisation, MAPK signalling, are attributed to PKC isoforms. These varied functions implicate PKC isoforms in cardiac hypertrophies and diabetic nephropathy and cardiovascular complications.
Anti-Protein Kinase C β2 antibody specifically recognizes an epitope located within the amino acid residues 660-673 at the C-terminal variable (V5) region of PKCβ2 (80 kDa).

Specificity

The antibody shows no cross-reactivity with PKC peptides corresponding to C-terminal sequences from PKC β1 (658-671) and PKC γ (684-697) conjugated to BSA.

Immunogen

synthetic peptide corresponding to the C-terminal variable (V5) region (amino acids 660-673) of PKC β2.

Application

Anti-Protein Kinase C β2 antibody may be used for immunoblotting at a working dilution of 1:8000 using rat brain cytosolic extract. It is suitable for protein microarray.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK Germany

3

Certificate of Analysis

Certificate of Origin

Yun Oh et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(7), 1135-1141 (2008-03-04)
Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses protein kinase C (PKC) and protein kinase B/AK transforming (AKT) signaling, induces tumor cell apoptosis, and inhibits proliferation and angiogenesis. Increased PKC and AKT activity is associated with poor prognosis in non-small-cell lung...
null
F Morschhauser et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 19(2), 247-253 (2007-10-02)
Protein kinase C beta (PKCbeta), a pivotal enzyme in B-cell signaling and survival, is overexpressed in most cases of mantle cell lymphoma (MCL). Activation of PI3K/AKT pathway is involved in pathogenesis of MCL. Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses...
Chava Perry et al.
Neoplasia (New York, N.Y.), 6(3), 279-286 (2004-05-22)
The cyclic adenosine monophosphate (AMP) response element-binding protein, CREB, often modulates stress responses. Here, we report that CREB suppresses the glioblastoma proliferative effect of the stress-induced acetylcholinesterase variant, AChE-R. In human U87MG glioblastoma cells, AChE-R formed a triple complex with...
S Budhiraja et al.
Fundamental & clinical pharmacology, 22(3), 231-240 (2008-05-20)
Diabetic nephropathy (DN) has emerged as the major causative pathology in patients entering end-stage renal disease (ESRD) worldwide and it is responsible for 30-40% of all ESRD cases. Treatments for DN are centered on control of hyperglycemia and blood pressure...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.